These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Listed as ongoing, but also has a completion date||2007-003042-15||A Phase 3, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis compar...||2009-05-04||bad-data|
|Ongoing||2011-004553-60||Safety and dose finding study of different MOD-4023 dose levels compared to daily r-hGH therapy in pre-pubertal growth hormone deficient children||not-yet-due|
|Not reported||2013-000830-37||A Phase 3, Multicenter Study Designed to Evaluate the Efficacy and Safety of a Long Acting hGH Product (MOD-4023) in Adult Subjects with Growth Hormone Deficiency||2018-11-19||due-trials|
|Ongoing||2016-003874-42||A phase 3, open-label, randomized, multicenter, 12 months, efficacy and safety study of weekly mod-4023 compared to daily genotropin® therapy in pre-pubertal children with growth hormone deficiency||not-yet-due|